ea0020p556 | Neuroendocrinology, Pituitary and Behaviour | ECE2009
, De Herder Wouter
, Janssen Joop
, Feelders Richard
, Van Der Lely Aart-Jan
Background: We previously reported on the efficacy, safety and Quality of Life of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA.Objective: To assess the long term safety in a larger group of acromegalic patients over a larger period of time; 29.2 (1.257.4) months (mean (range)).Design: Pegvisomant was added to SSA mono...